HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulation/Legislation (Health)

Set Alert for Regulation {Health}

Warnings Up As FDA Trims Its List Of Uninspected OTC Drug Manufacturers

Hundreds of foreign OTC drug firms marketing products in US had not been inspected for GMP compliance before FDA Safety and Innovation Act of 2012 pointed agency toward crossing those facilities off its list. Of the foreign OTC facilities inspected between June 2016 and January 2018, 25% received "official action indicated" inspection results, prompting warning letters and import alerts.

Health OTC Drugs Regulation

Swiss Regulatory Change Takes Over 500 OTCs Out Of Pharmacy

Swiss medicines authority, Swissmedic, rules that hundreds of non-prescription medicines are safe to be purchased outside pharmacy, following the completion of its review of the country's medicines classification system.
Regulation Prescription To Otc Switch Switzerland

France’s AFIPA Hits Back After Health Minister Takes Swipe At Self-Medication

French OTC industry association unhappy with health minister’s suggestion that certain non-reimbursed medicines are “useless”.

Health OTC Drugs Regulation


Set Alert for Regulation {Health}

Latest From Health & Regulation

Dietary Supplement Firms' Sun Protection Claims Scorched In NAD Review

National Advertising Division advises firms marketing supplements with claims to protect skin from sun rays to discontinue statements similar to claims made by four supplement firms FDA warned in May. Novahue and Dermatology Industry both disagreed with NAD but would comply with its recommendations.

Wellness Health

TummyZen Firm Appeals After Heartburn Claims Don't Settle Well In NAD Review

Eli Consumer Healthcare is latest supplement marketer National Advertising Division has advised that tests of separate ingredients do not support claims for a whole product. Following NADs review of TummyZen claims on challenge by Tums firm GlaxoSmithKline, Eli Consumer appeals NAD's recommendations to discontinue claims that its supplement “stops acid production,” is “acid inhibiting,” “halts the secretion of chloride ions in your parietal cells to regulate the release of acid into your stomach,” “supports stomach lining” and is “long lasting."

Wellness Health

French Public Throw Support Behind Homoeopathic Reimbursement

Homeopathy continues to come under the spotlight in Europe, with France the latest country to examine the value of reimbursing such products.

Health Consumer
See All


Set Alert for Legislation {Health}

Latest From Health & Legislation

'Lame Duck' Congress Has High Stakes For Pharma Companies

Industry faces an uphill fight in a last-ditch effort to reverse the Medicare “donut hole” changes enacted at the start of 2018. At the same time, a stand-off over OTC monograph reform could have ripple effects on the plans to modernize the US FDA Office of New Drugs.

Health OTC Drugs
See All